USFHP Prior Authorization Request Form for
ambrisentan (**Letairis**), macitentan (**Opsumit**)

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to:
Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

QUESTIONS? Call 1-877-880-7007
https://www.usfamilyhealth.org/for-providers/pharmacy-information/

Prior authorization does not expire. Clinical documentation may be required.

Step 1 — **Please complete patient and physician information** (please print):

Patient Name:		Physician Name:	
Address:		Address:	
Sponsor ID #		Phone #:	
Date of Birth:		Secure Fax #:	

Step 2 — **Please complete the clinical assessment:**

	Yes	No
1. **Does the patient have a documented diagnosis of WHO group 1 PAH?**	☐ Yes Proceed to question **2**	☐ No **STOP** **Coverage not approved**
2. **Is the requested medication being prescribed by or in consultation with a cardiologist or a pulmonologist?**	☐ Yes Proceed to question **3**	☐ No **STOP** **Coverage not approved**
3. **Has the patient had a right heart catheterization?**	☐ Yes Proceed to question **4**	☐ No **STOP** **Coverage not approved**
4. **Is documentation being provided to confirm that the patient has had a right heart catheterization?** PLEASE NOTE: Medical documentation specific to your response to this question must be attached to this case or your request could be denied. Documentation may include, but is not limited to, chart notes and catheterization laboratory reports.	☐ Yes Proceed to question **5**	☐ No **STOP** **Coverage not approved**
5. **Did the results of the right heart catheterization confirm the diagnosis of WHO Group 1 PAH?**	☐ Yes Proceed to question **6**	☐ No **STOP** **Coverage not approved**
6. **Is the patient male or female?**	☐ Male Proceed to question **10**	☐ Female Proceed to question **7**

	Yes	No
7. **Is the patient pregnant?**	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **8**
8. **Is the patient a woman of childbearing potential?**	☐ Yes Proceed to question **9**	☐ No Proceed to question **10**
9. **Is adequate contraception being used?**	☐ Yes Proceed to question **10**	☐ No **STOP** **Coverage not approved**
10. **Does the patient have history of liver function test (LFT) elevations on previous endothelin receptor antagonist (ERA) therapy, accompanied by signs or symptoms of liver toxicity or increases in bilirubin greater than two times the upper limit of normal?**	☐ Yes **STOP** **Coverage not approved**	☐ No Proceed to question **11**
11. **Does the patient have moderate or severe liver impairment (for example, Child-Pugh Class B or C)?**	☐ Yes **STOP** **Coverage not approved**	☐ No **Sign and date below**

Step 3

I certify the above is true to the best of my knowledge. Please sign and date:

_____   _____
Prescriber Signature   Date

[25 June 2025]